Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Editorial

Endocrine Disease as a Cause of Cardiovascular Disease: Current Perspectives

Author(s): Panagiotis Anagnostis, Dimitrios G. Goulis and Dimitri P. Mikhailidis

Volume 26, Issue 43, 2020

Page: [5547 - 5550] Pages: 4

DOI: 10.2174/1381612826666201203115443

Next »
[1]
Bosdou JK,, Anagnostis P,, Lainas GT,, et al. Kolibianakis EM. Female Infertility and Cardiovascular Risk - A Hype or an Underestimated Reality? Curr Pharm Des 2020; 26(43): 5551-6.
[2]
Lambrinoudaki I,, Stergiotis S,, Chatzivasileiou P,, et al. Anti-Mullerian Hormone Concentrations Are Inversely Associated With Subclinical Atherosclerosis in Premenopausal Women. Angiology 2020; 71: 552-8.
[3]
Wekker V, van Dammen L,, Koning A,, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update 2020; 26(6): 942-60.
[4]
Seaquist ER,, Anderson J,, Childs B,, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab 2013; 98: 1845-59.
[5]
Anagnostis P, Christou K, Artzouchaltzi AM, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol 2019; 180: 41-50.
[6]
Anagnostis P, Theocharis P, Lallas K, et al. Early menopause is associated with increased risk of arterial hypertension: A systematic review and meta-analysis. Maturitas 2020; 135: 74-9.
[7]
Zhu D, Chung HF, Dobson AJ, et al. Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies. Hum Reprod 2020; 35: 1933-43.
[8]
Sesti F, Pofi R, Pozza C, Minnetti M, Gianfrilli D, Kanakis GA. Cardiovascular Complications in Patients with Klinefelter’s Syndrome. Curr Pharm Des 2020; 26(43): 5556-63.
[9]
Kousta E, Kontogeorgi A, Robinson S, Johnston DG. Long-Term Metabolic Consequences in Patients with a History of Gestational Diabetes. Curr Pharm Des 2020; 26(43): 5564-72.
[10]
Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia 2019; 62: 905-14.
[11]
Yefet E, Schwartz N, Sliman B, Ishay A, Nachum Z. Good glycemic control of gestational diabetes mellitus is associated with the attenuation of future maternal cardiovascular risk: a retrospective cohort study. Cardiovasc Diabetol 2019; 18: 75.
[12]
Gogakos AI, Gogagos T, Kita T, Efstathiadou ZA. Pituitary Dysfunction as a Cause of Cardiovascular Disease. Curr Pharm Des 2020; 26(43): 5573-83.
[13]
Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2007; 92: 1743-7.
[14]
Parolin M, Dassie F, Alessio L, et al. Obstructive Sleep Apnea in Acromegaly and the Effect of Treatment: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2020; 105(3) dgz116
[15]
Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP, Drake WM. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. J Clin Endocrinol Metab 2018. In press
[16]
van Haalen FM, Broersen LH, Jorgensen JO, Pereira AM, Dekkers OM. Management of endocrine disease: Mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis. Eur J Endocrinol 2015; 172: R143-9.
[17]
Ivovic M, Marina LV, Sojat AS, et al. Approach to the Patient with Subclinical Cushing’s Syndrome. Curr Pharm Des 2020; 26(43): 5584-90.
[18]
Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol 2014; 2: 396-405.
[19]
Anagnostis P, Karras SN, Athyros VG, Mikhailidis DP, Karagiannis A. Subclinical Cushing’s syndrome and cardiovascular disease. Lancet Diabetes Endocrinol 2014; 2: 361.
[20]
Kotanidou EP, Giza S, Tsinopoulou V-R, Vogiatzi M, Galli-Tsinopoulou A. Diagnosis and Management of Endocrine Hypertension in Children and Adolescents. Curr Pharm Des 2020; 26(43): 5591-608.
[21]
Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med 2011; 365: 1876-85.
[22]
Livadas S, Bothou C, Macut D. Premature Adrenarche and its Association with Cardiovascular Risk in Females. Curr Pharm Des 2020; 26(43): 5609-16.
[23]
Wu TT, Chen Y, Zhou Y, et al. Prognostic Value of Dehydroepiandrosterone Sulfate for Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2017; 6.
[24]
Wu TT, Gao Y, Zheng YY, Ma YT, Xie X. Association of endogenous DHEA/DHEAS with coronary heart disease: A systematic review and meta-analysis. Clin Exp Pharmacol Physiol 2019; 46: 984-94.
[25]
Stojkovic M, Zarkovic M. Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease. Curr Pharm Des 2020; 26(43): 5617-27.
[26]
Tournis S, Makris K, Cavalier E, Trovas G. Cardiovascular Risk in Patients with Primary Hyperparathyroidism. Curr Pharm Des 2020; 26(43): 5628-36.
[27]
Katsiki N, Kotsa K, Stoian AP, Mikhailidis DP. Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes. Curr Pharm Des 2020; 26(43): 5637-49.
[28]
Kostopoulou E, Bosdou JK, Anagnostis P, Stevenson JC, Goulis DG. Cardiovascular Complications in Patients with Turner’s Syndrome. Curr Pharm Des 2020; 26(43): 5650-9.
[29]
Pu Z, Lai L, Yang X, et al. Acute glycemic variability on admission predicts the prognosis in hospitalized patients with coronary artery disease: a meta-analysis. Endocrine 2020; 67: 526-34.

© 2024 Bentham Science Publishers | Privacy Policy